Trial Profile
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2014
Price :
$35
*
At a glance
- Drugs Vesencumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 19 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.